Humacyte, Inc. Total Shareholder Rtn Amt
Humacyte, Inc. (HUMA) reported Total Shareholder Rtn Amt of $33.8 for the 12-month period ending 2025-12-31, per its DEF 14A filed 2026-04-28.
Financial Statements › Notes
ecd:TotalShareholderRtnAmt · last filed 2026-04-28
| Period end | Total Shareholder Rtn Amt 12 month |
|---|---|
| 2025-12-31 | $33.80 DEF 14A · filed 2026-04-28 |
| 2024-12-31 | $177.82 DEF 14A · filed 2026-04-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |